Article(id=1327671938509550433, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327671856833868058, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2022.11.016, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1661702400000, receivedDateStr=2022-08-29, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794471257091, onlineDateStr=2026-11-12, pubDate=1668009600000, pubDateStr=2022-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794471257091, onlineIssueDateStr=2026-11-12, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794471257091, creator=13701087609, updateTime=1794471257091, updator=13701087609, issue=Issue{id=1327671856833868058, tenantId=1146029695717560320, journalId=1319690259887390882, year='2022', volume='53', issue='11', pageStart='1529', pageEnd='1670', issueExtLink='null', onlineDate='null', pubDate='1668009600000', pubDateStr='2022-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794471237619, creator='13701087609', updateTime=1794472094917, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1327675453114004391, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327671856833868058, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1327675453114004392, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327671856833868058, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1622, endPage=1627, ext={EN=ArticleExt(id=1327671938689905506, articleId=1327671938509550433, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Analysis of the Application of Model-informed Drug Development in Pediatric Drug Development Taking Rivaroxaban Granules for Oral Suspension as an Example, columnId=null, journalTitle=Chinese Journal of Pharmaceuticals, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Rivaroxaban granules for oral suspension was approved by FDA in 2021 for the treatment of venous thromboembolism(VTE) and prevention of VTE recurrence in patients under age of 18 years after at least 5 days of initial parenteral anticoagulation treatment. The development of rivaroxaban granules for oral suspension for pediatric indications was based on adult data. Model-informed drug development method was adopted to support the initial dosage selection in pediatric clinical trials, dose adjustment of phase Ⅱ and Ⅲ clinical trials. This paper analyzes the relative pediatric studies and FDA’s evaluation considerations of rivaroxaban granules for oral suspension, and discusses the application of model-informed drug development in pediatric drug development.

, authors=Pengyu PAN1, Hongcan HAN1, Jinjing CHE2, Jun WANG1, *, authorsList=Pengyu PAN, Hongcan HAN, Jinjing CHE, Jun WANG, authorCompany=null, correspAuthors=Jun WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1327671939050615651, articleId=1327671938509550433, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=以利伐沙班干混悬剂为例分析模型引导的药物研发在儿科药物开发中的应用, columnId=1327671857534316828, journalTitle=中国医药工业杂志, columnName=本期主题:儿童药创新研发与科学监管, runingTitle=null, highlight=null, articleAbstract=

利伐沙班干混悬剂于2021年被美国FDA批准用于至18岁以下患者,在至少5 d的初始肠外抗凝治疗后,使用利伐沙班治疗静脉血栓栓塞(VTE)及降低复发性VTE的风险。利伐沙班干混悬剂作为儿科药物开发时是基于成人临床研究数据,采用模型引导的药物研发方式对儿科临床试验中的初始剂量选择、Ⅱ期和Ⅲ期临床试验的剂量调整提供支持。本研究分析了利伐沙班干混悬剂儿科研究的相关内容和FDA的评价考虑,讨论模型引导的药物研发在儿科药物开发中的作用。

, authors=潘鹏玉1, 韩鸿璨1, 车津晶2, 王骏1, *, authorsList=潘鹏玉, 韩鸿璨, 车津晶, 王骏, authorCompany=null, correspAuthors=王骏, authorNote=

潘鹏玉(1988—),女,主管药师,从事药品技术审评工作。

, correspAuthorsNote=
王骏(1979—),男,研究员,从事药品技术审评工作。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=QPw+vRcR1CyYCLi+hrf+EA==, magXml=bq8iUJ8NL2p9HzMNw//chA==, pdfUrl=null, pdf=VsJvO/KoWIbGMzwubGjlPA==, pdfFileSize=1560467, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=5Qp47iBu/4QTwoIJZz4hsg==, mapNumber=null, fund=null)}, authors=[Author(id=1327672097003909135, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672097075212305, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097003909135, language=EN, stringName=Pengyu PAN, firstName=Pengyu, middleName=null, lastName=PAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672097146515474, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097003909135, language=CN, stringName=潘鹏玉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.国家药品监督管理局药品审评中心,北京 100022, bio={"content":"

潘鹏玉(1988—),女,主管药师,从事药品技术审评工作。

"}, bioImg=null, bioContent=

潘鹏玉(1988—),女,主管药师,从事药品技术审评工作。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1327672097213624340, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672097297510422, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097213624340, language=EN, stringName=Hongcan HAN, firstName=Hongcan, middleName=null, lastName=HAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672097381396503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097213624340, language=CN, stringName=韩鸿璨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1327672099071701017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672099163975707, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099071701017, language=EN, stringName=Jinjing CHE, firstName=Jinjing, middleName=null, lastName=CHE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672099298193436, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099071701017, language=CN, stringName=车津晶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.军事医学研究院毒物药物研究所,北京 100850, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096840331275, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=2., ext=[AuthorCompanyExt(id=1327672096848719884, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096840331275, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850), AuthorCompanyExt(id=1327672096869691405, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096840331275, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.军事医学研究院毒物药物研究所,北京 100850)])]), Author(id=1327672099373690910, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=wangj@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327672099453382688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099373690910, language=EN, stringName=Jun WANG, firstName=Jun, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672099533074465, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099373690910, language=CN, stringName=王骏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)])])], keywords=[Keyword(id=1327672099684069410, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=EN, orderNo=1, keyword=rivaroxaban granules for oral suspension), Keyword(id=1327672099763761187, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=EN, orderNo=2, keyword=pediatric drug), Keyword(id=1327672099826675748, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=EN, orderNo=3, keyword=dose selection), Keyword(id=1327672099881201701, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=EN, orderNo=4, keyword=model-informed drug development), Keyword(id=1327672099935727654, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=CN, orderNo=1, keyword=利伐沙班干混悬剂), Keyword(id=1327672099998642215, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=CN, orderNo=2, keyword=儿科药物), Keyword(id=1327672100069945384, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=CN, orderNo=3, keyword=剂量选择), Keyword(id=1327672100124471337, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, language=CN, orderNo=4, keyword=模型引导的药物研发)], refs=[Reference(id=1327672100254494762, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.关于发布《模型引导的药物研发技术指导原则》的通告(2020年第59号)[EB/OL].(2020-12-31)[2022-07-26].https://www.cde.org.cn/main/news/viewInfoCommon/23b634adf79ecd4616bb91bcd66815f0., articleTitle=null, refAbstract=null), Reference(id=1327672100325797931, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=US Food & Drug Administration.Label of XARELTO(rivaroxaban) for oral suspension [EB/OL] (2021-12-20) [2022-07-26].https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859Orig1s000correctedLBL.pdf., articleTitle=null, refAbstract=null), Reference(id=1327672100392906796, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=US Food & Drug Administration.Clinical pharmacology and biopharmaceutics review(s) [EB/OL].(2021-12-20) [2022-07-26].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215859Orig1s000ClinPharmR.pdf., articleTitle=null, refAbstract=null), Reference(id=1327672100455821357, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.关于发布《儿科用药临床药理学研究技术指导原则》的通告(2020年第70号)[EB/OL].(2020-12-31)[2022-07-26].https://www.cde.org.cn/main/news/viewInfoCommon/eedbe795dfe1d3ab2694c84e786e446e., articleTitle=null, refAbstract=null), Reference(id=1327672100522930222, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=WILLMANN S, THELEN K, KUBITZA D, et al.Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study [J].Thromb J,2018, 16: 32., articleTitle=null, refAbstract=null), Reference(id=1327672100585844783, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=WILLMANN S, COBOEKEN K, ZHANG Y, et al.Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions [J].CPT Pharmacometrics Syst Pharmacol, 2021, 10(10): 1195-1207., articleTitle=null, refAbstract=null), Reference(id=1327672100644565040, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=MAHARAJ A R, EDGINTON A N.Physiologically based pharmacokinetic modeling and simulation in pediatric drug development [J].CPT Pharmacometrics Syst Pharmacol,2014, 3(11): e150., articleTitle=null, refAbstract=null), Reference(id=1327672100728451121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=LEONG R, VIEIRA M L, ZHAO P, et al.Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials [J].Clin Pharmacol Ther,2012, 91(5): 926-931., articleTitle=null, refAbstract=null), Reference(id=1327672100795559986, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=JOHNSON T N, SMALL B G, BERGLUND E G, et al.A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development[J].CPT Pharmacometrics Syst Pharmacol, 2021, 10(9):967-972., articleTitle=null, refAbstract=null), Reference(id=1327672100850085939, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=INCE I, DALLMANN A, FRECHEN S, et al.Predictive performance of physiology-based pharmacokinetic dose estimates for pediatric trials: evaluation with 10 Bayer small-molecule compounds in children [J].J Clin Pharmacol,2021, 61(Suppl 1): S70-S82., articleTitle=null, refAbstract=null), Reference(id=1327672100913000500, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=EDGINTON A N, SCHMITT W, VOITH B, et al.A mechanistic approach for the scaling of clearance in children[J].Clin Pharmacokinet, 2006, 45(7): 683-704., articleTitle=null, refAbstract=null), Reference(id=1327672100975915061, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=韩鸿璨,王骏,李栋,等.模型引导的药物研发在儿科人群用药研究中的应用及策略[J].中国临床药理学杂志,2021,37(22):3193-3198., articleTitle=null, refAbstract=null), Reference(id=1327672101038829622, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=STATELOVA M, HOLM R, FOTAKI N, et al.Factors affecting successful extrapolation of ibuprofen exposure from adults to pediatric populations after oral administration of a pediatric aqueous suspension [J].AAPS J, 2020, 22(6):146., articleTitle=null, refAbstract=null), Reference(id=1327672101093355575, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=STATELOVA M, HOLM R, FOTAKI N, et al.Successful extrapolation of paracetamol exposure from adults to infants after oral administration of a pediatric aqueous suspension is highly dependent on the study dosing conditions [J].AAPS J, 2020, 22(6):126., articleTitle=null, refAbstract=null), Reference(id=1327672101173047352, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG J, VAN DEN ANKER J N, BURCKART G J.Progress in drug development-pediatric dose selection: workshop summary [J].J Clin Pharmacol, 2021, 61(Suppl 1): S13-S21., articleTitle=null, refAbstract=null), Reference(id=1327672101240156217, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=MAREK E, MOMPER J D, HINES R N, et al.Prediction of warfarin dose in pediatric patients: an evaluation of the predictive performance of several models [J].J Pediatr Pharmacol Ther, 2016, 21(3): 224-232., articleTitle=null, refAbstract=null), Reference(id=1327672101324042298, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM C, PARK K, MCMAHON A W, et al.Drug safety in labeling for pediatric drug development and dose selection in submissions to the US Food and Drug Administration [J].J Clin Pharmacol, 2021, 61(Suppl 1): S133-S140., articleTitle=null, refAbstract=null), Reference(id=1327672101386956859, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=GREEN F G, PARK K, BURCKART G J.Methods used for pediatric dose selection in drug development programs submitted to the US FDA 2012-2020 [J].J Clin Pharmacol, 2021, 61(Suppl 1): S28-S35., articleTitle=null, refAbstract=null), Reference(id=1327672101441482812, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=BURCKART G J, VAN DEN ANKER J N.Neonatal and pediatric dose selection: Quo Vadis? [J].J Clin Pharmacol,2021, 61(Suppl 1): S7-S8., articleTitle=null, refAbstract=null), Reference(id=1327672101504397373, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=CLEARY Y, GERTZ M, GRIMSEY P, et al.Model-based drug-drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy [J].Clin Pharmacol Ther, 2021, 110(6): 1547-1557., articleTitle=null, refAbstract=null), Reference(id=1327672101584089150, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=HUANG W, NAKANO M, SAGER J, et al.Physiologically based pharmacokinetic model of the CYP2D6 probe atomoxetine: extrapolation to special populations and drug-drug interactions [J].Drug Metab Dispos, 2017, 45(11):1156-1165., articleTitle=null, refAbstract=null), Reference(id=1327672101663780927, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=ABDEL-RAHMAN S M, AMIDON G L, KAUL A, et al.Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group[J].Clin Ther, 2012, 34(11): S11-S24., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)]), AuthorCompany(id=1327672096840331275, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=2., ext=[AuthorCompanyExt(id=1327672096848719884, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096840331275, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850), AuthorCompanyExt(id=1327672096869691405, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096840331275, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.军事医学研究院毒物药物研究所,北京 100850)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.11.016, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.11.016, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2022.11.016, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2022.11.016, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1668009600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
以利伐沙班干混悬剂为例分析模型引导的药物研发在儿科药物开发中的应用
潘鹏玉 1 , 韩鸿璨 1 , 车津晶 2 , 王骏 1, *
中国医药工业杂志 | 本期主题:儿童药创新研发与科学监管 2022,53(11): 1622-1627
收起
收藏切换
中国医药工业杂志 |本期主题:儿童药创新研发与科学监管 2022 , 53 (11) : 1622 -1627
以利伐沙班干混悬剂为例分析模型引导的药物研发在儿科药物开发中的应用
全屏
[Author(id=1327672097003909135, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672097075212305, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097003909135, language=EN, stringName=Pengyu PAN, firstName=Pengyu, middleName=null, lastName=PAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672097146515474, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097003909135, language=CN, stringName=潘鹏玉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.国家药品监督管理局药品审评中心,北京 100022, bio={"content":"

潘鹏玉(1988—),女,主管药师,从事药品技术审评工作。

"}, bioImg=null, bioContent=

潘鹏玉(1988—),女,主管药师,从事药品技术审评工作。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1327672097213624340, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672097297510422, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097213624340, language=EN, stringName=Hongcan HAN, firstName=Hongcan, middleName=null, lastName=HAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672097381396503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672097213624340, language=CN, stringName=韩鸿璨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1327672099071701017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672099163975707, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099071701017, language=EN, stringName=Jinjing CHE, firstName=Jinjing, middleName=null, lastName=CHE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672099298193436, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099071701017, language=CN, stringName=车津晶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.军事医学研究院毒物药物研究所,北京 100850, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096840331275, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=2., ext=[AuthorCompanyExt(id=1327672096848719884, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096840331275, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850), AuthorCompanyExt(id=1327672096869691405, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096840331275, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.军事医学研究院毒物药物研究所,北京 100850)])]), Author(id=1327672099373690910, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=wangj@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327672099453382688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099373690910, language=EN, stringName=Jun WANG, firstName=Jun, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672099533074465, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, authorId=1327672099373690910, language=CN, stringName=王骏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672096756445192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, xref=1., ext=[AuthorCompanyExt(id=1327672096769028105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022), AuthorCompanyExt(id=1327672096777416714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327671938509550433, companyId=1327672096756445192, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.国家药品监督管理局药品审评中心,北京 100022)])])]
潘鹏玉1, 韩鸿璨1, 车津晶2, 王骏1, *
作者信息
  • 1.国家药品监督管理局药品审评中心,北京 100022
  • 2.军事医学研究院毒物药物研究所,北京 100850
通讯作者:
王骏(1979—),男,研究员,从事药品技术审评工作。E-mail:
作者简介:

潘鹏玉(1988—),女,主管药师,从事药品技术审评工作。

Analysis of the Application of Model-informed Drug Development in Pediatric Drug Development Taking Rivaroxaban Granules for Oral Suspension as an Example
Pengyu PAN1, Hongcan HAN1, Jinjing CHE2, Jun WANG1, *
Affiliations
  • 1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022
  • 2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850
出版时间: 2022-11-10 doi: 10.16522/j.cnki.cjph.2022.11.016
文章导航
收藏切换

利伐沙班干混悬剂于2021年被美国FDA批准用于至18岁以下患者,在至少5 d的初始肠外抗凝治疗后,使用利伐沙班治疗静脉血栓栓塞(VTE)及降低复发性VTE的风险。利伐沙班干混悬剂作为儿科药物开发时是基于成人临床研究数据,采用模型引导的药物研发方式对儿科临床试验中的初始剂量选择、Ⅱ期和Ⅲ期临床试验的剂量调整提供支持。本研究分析了利伐沙班干混悬剂儿科研究的相关内容和FDA的评价考虑,讨论模型引导的药物研发在儿科药物开发中的作用。

利伐沙班干混悬剂  /  儿科药物  /  剂量选择  /  模型引导的药物研发

Rivaroxaban granules for oral suspension was approved by FDA in 2021 for the treatment of venous thromboembolism(VTE) and prevention of VTE recurrence in patients under age of 18 years after at least 5 days of initial parenteral anticoagulation treatment. The development of rivaroxaban granules for oral suspension for pediatric indications was based on adult data. Model-informed drug development method was adopted to support the initial dosage selection in pediatric clinical trials, dose adjustment of phase Ⅱ and Ⅲ clinical trials. This paper analyzes the relative pediatric studies and FDA’s evaluation considerations of rivaroxaban granules for oral suspension, and discusses the application of model-informed drug development in pediatric drug development.

rivaroxaban granules for oral suspension  /  pediatric drug  /  dose selection  /  model-informed drug development
潘鹏玉, 韩鸿璨, 车津晶, 王骏. 以利伐沙班干混悬剂为例分析模型引导的药物研发在儿科药物开发中的应用. 中国医药工业杂志, 2022 , 53 (11) : 1622 -1627 . DOI: 10.16522/j.cnki.cjph.2022.11.016
Pengyu PAN, Hongcan HAN, Jinjing CHE, Jun WANG. Analysis of the Application of Model-informed Drug Development in Pediatric Drug Development Taking Rivaroxaban Granules for Oral Suspension as an Example[J]. Chinese Journal of Pharmaceuticals, 2022 , 53 (11) : 1622 -1627 . DOI: 10.16522/j.cnki.cjph.2022.11.016

参考文献 引证文献
排序方式:
[1]
国家药品监督管理局药品审评中心.关于发布《模型引导的药物研发技术指导原则》的通告(2020年第59号)[EB/OL].(2020-12-31)[2022-07-26].https://www.cde.org.cn/main/news/viewInfoCommon/23b634adf79ecd4616bb91bcd66815f0.
[2]
US Food & Drug Administration.Label of XARELTO(rivaroxaban) for oral suspension [EB/OL] (2021-12-20) [2022-07-26].https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859Orig1s000correctedLBL.pdf.
[3]
US Food & Drug Administration.Clinical pharmacology and biopharmaceutics review(s) [EB/OL].(2021-12-20) [2022-07-26].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215859Orig1s000ClinPharmR.pdf.
[4]
国家药品监督管理局药品审评中心.关于发布《儿科用药临床药理学研究技术指导原则》的通告(2020年第70号)[EB/OL].(2020-12-31)[2022-07-26].https://www.cde.org.cn/main/news/viewInfoCommon/eedbe795dfe1d3ab2694c84e786e446e.
[5]
WILLMANN S, THELEN K, KUBITZA D, et al.Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study [J].Thromb J,2018, 16: 32.
[6]
WILLMANN S, COBOEKEN K, ZHANG Y, et al.Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions [J].CPT Pharmacometrics Syst Pharmacol, 2021, 10(10): 1195-1207.
[7]
MAHARAJ A R, EDGINTON A N.Physiologically based pharmacokinetic modeling and simulation in pediatric drug development [J].CPT Pharmacometrics Syst Pharmacol,2014, 3(11): e150.
[8]
LEONG R, VIEIRA M L, ZHAO P, et al.Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials [J].Clin Pharmacol Ther,2012, 91(5): 926-931.
[9]
JOHNSON T N, SMALL B G, BERGLUND E G, et al.A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development[J].CPT Pharmacometrics Syst Pharmacol, 2021, 10(9):967-972.
[10]
INCE I, DALLMANN A, FRECHEN S, et al.Predictive performance of physiology-based pharmacokinetic dose estimates for pediatric trials: evaluation with 10 Bayer small-molecule compounds in children [J].J Clin Pharmacol,2021, 61(Suppl 1): S70-S82.
[11]
EDGINTON A N, SCHMITT W, VOITH B, et al.A mechanistic approach for the scaling of clearance in children[J].Clin Pharmacokinet, 2006, 45(7): 683-704.
[12]
韩鸿璨,王骏,李栋,等.模型引导的药物研发在儿科人群用药研究中的应用及策略[J].中国临床药理学杂志,2021,37(22):3193-3198.
[13]
STATELOVA M, HOLM R, FOTAKI N, et al.Factors affecting successful extrapolation of ibuprofen exposure from adults to pediatric populations after oral administration of a pediatric aqueous suspension [J].AAPS J, 2020, 22(6):146.
[14]
STATELOVA M, HOLM R, FOTAKI N, et al.Successful extrapolation of paracetamol exposure from adults to infants after oral administration of a pediatric aqueous suspension is highly dependent on the study dosing conditions [J].AAPS J, 2020, 22(6):126.
[15]
WANG J, VAN DEN ANKER J N, BURCKART G J.Progress in drug development-pediatric dose selection: workshop summary [J].J Clin Pharmacol, 2021, 61(Suppl 1): S13-S21.
[16]
MAREK E, MOMPER J D, HINES R N, et al.Prediction of warfarin dose in pediatric patients: an evaluation of the predictive performance of several models [J].J Pediatr Pharmacol Ther, 2016, 21(3): 224-232.
[17]
KIM C, PARK K, MCMAHON A W, et al.Drug safety in labeling for pediatric drug development and dose selection in submissions to the US Food and Drug Administration [J].J Clin Pharmacol, 2021, 61(Suppl 1): S133-S140.
[18]
GREEN F G, PARK K, BURCKART G J.Methods used for pediatric dose selection in drug development programs submitted to the US FDA 2012-2020 [J].J Clin Pharmacol, 2021, 61(Suppl 1): S28-S35.
[19]
BURCKART G J, VAN DEN ANKER J N.Neonatal and pediatric dose selection: Quo Vadis? [J].J Clin Pharmacol,2021, 61(Suppl 1): S7-S8.
[20]
CLEARY Y, GERTZ M, GRIMSEY P, et al.Model-based drug-drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy [J].Clin Pharmacol Ther, 2021, 110(6): 1547-1557.
[21]
HUANG W, NAKANO M, SAGER J, et al.Physiologically based pharmacokinetic model of the CYP2D6 probe atomoxetine: extrapolation to special populations and drug-drug interactions [J].Drug Metab Dispos, 2017, 45(11):1156-1165.
[22]
ABDEL-RAHMAN S M, AMIDON G L, KAUL A, et al.Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group[J].Clin Ther, 2012, 34(11): S11-S24.
2022年第53卷第11期
68
10
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2022.11.016
  • 接收时间:2022-08-29
  • 首发时间:2026-11-12
  • 出版时间:2022-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-08-29
基金
作者信息
    1.国家药品监督管理局药品审评中心,北京 100022
    2.军事医学研究院毒物药物研究所,北京 100850

通讯作者:

王骏(1979—),男,研究员,从事药品技术审评工作。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.11.016
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏